Table 1 Summary of study characteristics |
|
|
|
|
|
Reference (year)
|
Study design
|
Design of intervention
|
Age at diagnosis (Mean age, years)
(Time since treatment (Mean time since diagnosis, years))
|
Experimental Sample
(Mean age at pre-intervention)
|
Control sample
(Mean age at pre-intervention)
|
Riggs et al. (2017)
|
Open-label, RCT with crossover
|
Exercise training
(Group setting: 3x 90min/week, 12 weeks
Home setting: 2x 90min/week, 2x 30min/week, 12 weeks)
|
Mean age: Training first group 11.19±2.98 (5.53±2.38)
No training first group 12±3 (5.88±3.41)
|
n=28, all hemispheric or posterior fossa tumors with heterogeneous
therapies
(Mean age: Training first group 5.61±2.61, No Training first group
6.33±1.56)
|
n=28, typically developing control
|
Szulc-Lerch et al. (2018)
|
Open-label, RCT with crossover
|
Exercise training
(Group setting: 3x 90min/week, 12 weeks
Home setting: 2x 90min/week, 2x 30min/week, 12 weeks)
|
Mean age: Training first group 11.19±2.98 (5.53±2.38)
No training first group 12±3 (5.88±3.41)
|
n=28, all hemispheric or posterior fossa tumors with heterogeneous
therapies
(Mean age: Training first group 5.61±2.61, No Training first group
6.33±1.56)
|
n=28, typically developing control
|
Cox et al. (2020)
|
Open-label, RCT with crossover
|
Exercise training
(Group setting: 3x 90min/week, 12 weeks
Home setting: 2x 90min/week, 2x 30min/week, 12 weeks)
|
Mean age: Training first group 5.77±2.75 (5.28±2.40)
No training first group 6.56±1.64 (5.86±3.43)
|
n=25, all hemispheric or posterior fossa tumors with heterogeneous
therapies
(Mean age: Training first group 11.10±3.19, No Training first group
12.47±2.94)
|
n=25, typically developing control
|
Rath et al. (2018)
|
Longitudinal Single-arm, Open-Label
|
Individually tailored exercise training
(3x/week, 24 weeks)
|
Mean age: 3.9 (11.1)
|
n=20, heterogeneous cancer, and treatment types
(Mean age:19.8)
|
N.A.
|
Fontana et al. (2021)
|
Open-Label, RCT with crossover
|
Purely physical or physical and attentional exercises
(60min/week, 10 months)
|
N.R.
|
n=20, heterogeneous cancer, and treatment types
(Mean age: 10.8)
|
N.A.
|
Kanitz et al. (2013)
|
Longitudinal Single-arm, Open-Label
|
Eurythmy Therapy
(25 hours, 6 months)
|
Mean age: 7.1±3.2 (/)
|
n=7, all cerebellar tumors with heterogeneous therapies
(Mean age: 11.16±4.37)
|
N.A.
|
Patel et al. (2009)
|
Longitudinal Single-arm, Open-Label
|
Cognitive and Problem-solving training
(15 weeks, 60-90 min/session)
|
Mean age 5.96±4.86 (7.23±2.75)
|
n=12, heterogeneous cancer, and treatment types
(Mean age: 11.75±3.77)
|
N.A.
|
Conklin et al. (2015)
|
Single-blinded RCT
|
Cogmed
(25 sessions of 30-45 min/session, 5-9 weeks)
|
Mean age: Cogmed 5.15±2.92 (4.97±3.02)
Control 4.62±2.68 (5.04±2.41)
|
n=34, heterogeneous cancer types treated with RT and/or intrathecal ChT,
(Mean age: 12.21±2.47)
|
n=34, heterogeneous cancer types treated with RT and/or intrathecal ChT,
(Mean age: 11.82±2.42)
|
Conklin et al. (2017)
|
Single-blinded RCT
|
Cogmed
(25 sessions of 30-45 min/session, 5-9 weeks)
|
Mean age: Cogmed 5.15±2.92 (4.97±3.02)
Control 4.62±2.68 (5.04±2.41)
|
n=34, heterogeneous cancer types treated with RT and/or intrathecal ChT,
(Mean age: 12.21±2.47)
|
n=34, heterogeneous cancer types treated with RT and/or intrathecal ChT,
(Mean age: 11.82±2.42)
|
Table 1 (continued) |
|
|
|
|
|
Reference (year)
|
Study design
|
Design of intervention
|
Age at diagnosis (Mean age, years)
(Time since treatment (Mean time since diagnosis, years))
|
Experimental Sample
(Mean age at pre-intervention)
|
Control sample
(Mean age at pre-intervention)
|
Hardy et al. (2013)
|
Double-blinded RCT
|
Cogmed or MegaMemo
(25 sessions of 30-45 min/session, 5-8 weeks)
|
Mean age: Cogmed 4.9±3.54 (6.0±2.98)
Control 5.7±2.88 (3.0±1.77)
|
n=14, heterogeneous cancer, and treatment types, (Mean age:
12.7±2.77)
|
n=7, heterogeneous cancer, and treatment types, (Mean age:
10.7±1.89)
|
Siciliano et al. (2021) |
Single-blinded RCT |
Cogmed: adaptive or non-adaptive
(25
sessions of 30-45 min/session, 5 weeks)
|
N.R. |
n=20, all brain
tumors with heterogeneous therapies, (Mean age: 11.98±2.68) |
n=21, all
brain tumors with heterogeneous therapies, (Mean age:
11.98±2.68) |
Carlson-Green et al. (2017)
|
Longitudinal Single-arm, Open-Label
|
Cogmed
(35 sessions of 30-45 min/session, 8-10 weeks)
|
Mean age: 6 (5)
|
n=21, all brain tumors with heterogeneous therapies, (/)
|
N.A.
|
Peterson et al. (2022) |
Longitudinal Single-arm, Open-Label |
Cogmed or JumpMath
(40 sessions, 30
min./session, 12 weeks)
|
Mean age: Cogmed 7.87 (5.36), JumpMath 4.49
(6.01), Control 4.70 (5.55) |
Cogmed: n=10, (Mean age: 13.71), Jumpmath:
n=9, (Mean age: 10.56), all brain tumors with cranial RT |
n=9, all
brain tumors with cranial RT, (Mean age: 10.28) |
Palmer et al. (2014) |
Open-Label, Single-blinded RCT |
Fast ForWord
(30 sessions of 48
min/session, 5 sessions/week, 6 weeks)
|
N.R. |
n=43, all
medulloblastoma with CSI and ChT, (Mean age: 9.38) |
n=38, all
medulloblastoma with CSI and ChT, (Mean age: 9.27) |
Zou et al. (2016)
|
Open-Label, Single-blinded RCT
|
Fast ForWord
(30 sessions of 48 min/session, 5 sessions/week, 6 weeks)
|
Mean age: Fast ForWord 10 (2.8), Control 9.5 (2.5)
|
n=21, all medulloblastoma with CSI and ChT, (Mean age: 11.7)
|
n=21, all medulloblastoma with CSI and ChT, (Mean age: 12.1);
n=21, typically developing children, (Mean age: 12.3)
|
Hardy et al. (2011) |
Longitudinal Single-arm, Open-Label |
Captain’s Log
(50 min/week for 12
weeks)
|
Mean age: N.R. (5.7±3.20) |
n=9, heterogeneous cancer, and
treatment types, (Mean age: 13.3±2.44) |
N.A. |
Butler et al. (2008) |
Open-Label, RCT |
Cognitive
Remediation Program
(20x 120min/week, 4-5 months)
|
Mean
age: CRP 4.9±3.3 (5.8±2.8), Control 5.6±3.4 (5.6±3.2) |
n=108,
heterogeneous disease, (Mean age: 10.8±3.4) |
n=53, heterogeneous
disease, (Mean age: 11.1±3.1) |
Zou et al. (2012) |
Open-Label, RCT |
Cognitive
Remediation Program
(20x 120min/week, 4-5 months)
|
Mean
age: CRP 5.0, Control 5.8 |
n=8, heterogeneous cancer, (Mean age: 13.36) |
n=6, heterogeneous cancer, (Mean age:
10.5)
n=28, typically developing children, (Mean
age:12.7)
|
Kesler et al. (2011) |
Longitudinal Single-arm, Open-Label |
Cognitive Rehabilitation Curriculum
(40
sessions, 5 sessions/week, 20 min/session, 8 weeks)
|
Mean age: N.R.
(3.1±2.5) |
n=23, heterogeneous cancer, and treatment types, (Mean age:
12.6±4.1) |
N.A. |
Wade et al. (2020) |
Longitudinal Single-arm, Open-Label |
A Survivor’s Journey
(Independently
online modules and weekly therapist session, 2-4 months)
|
Mean age:
6.83±3 (8.85±4) |
n=19, all brain tumors with heterogeneous treatment
types, (Mean age: 17.6±3) |
N.A. |
Table 1 (continued) |
|
|
|
|
|
Reference (year)
|
Study design
|
Design of intervention
|
Age at diagnosis (Mean age, years)
(Time since treatment (Mean time since diagnosis, years))
|
Experimental Sample
(Mean age at pre-intervention)
|
Control sample
(Mean age at pre-intervention)
|
De Ruiter et al. (2016) |
Double-Blind RCT |
Neurofeedback training
(30 sessions, 30
min/session)
|
Mean age: Neurofeedback group
6.81±3.65 (7.64±4.04)
Control sample 7.42±4.09
(6.03±2.99)
|
n= 34, all brain tumors with
heterogeneous therapies
(Mean age: 14.45±2.99)
|
n=37, all brain tumors with heterogeneous
therapies
(Mean age: 13.45±3.28)
|
Thompson et al. (2001) |
Double-Blind RCT with crossover |
Methylphenidate
(Single does, 0.60
mg/kg)
|
Mean age: MPH group 3.5, Control 4.8 |
n=15, heterogeneous
cancer types with ChT +/- RT, (Mean age: 11.3) |
n=17, heterogeneous
cancer types with ChT +/- RT, (Mean age: 11.8) |
Conklin et al. (2007) |
Double-Blind RCT with crossover |
Methylphenidate
(Single does, 0.60
mg/kg)
|
Mean age at cancer treatment: 5.29±2.91 (4.71±2.90) |
n=122,
heterogeneous cancer types with ChT +/- RT, (Mean age: 11.76±2.30) |
N.A. |
Mulhern et al. (2004) |
Double-Blind RCT with crossover |
Methylphenidate
(5 days MPH
administration, LD: 0.30 mg/kg, HD: 0.60 mg/kg, Placebo)
|
Mean age:
5.4±3.02 (4.9±3.12) |
n=83, heterogeneous cancer types with ChT +/- RT,
(Mean age: 11.9±3.12) |
N.A. |
Conklin et al. (2010) |
Double-Blind RCT with crossover |
Methylphenidate
(5 days MPH
administration, LD: 0.30 mg/kg, HD: 0.60 mg/kg, Placebo)
|
Mean age:
5.41±2.87 (4.70±2.92) |
n=106, heterogeneous cancer types with ChT +/-
RT, (Mean age: 11.92±3.00) |
N.A. |
Conklin, Reddick et al. (2010) |
Longitudinal Single-arm, Open-Label |
Methylphenidate
(Individually titrated
MPH dose, 12 months)
|
Mean age: MPH group 5.21, SE 0.36 (4.26, SE
0.32); Control 5.43, SE 0.43 (4.35, SE 0.36) |
n=68, heterogeneous
cancer types with ChT +/- RT, (Mean age: 11.11, SE 0.37) |
n=54,
heterogeneous cancer types with ChT +/- RT, (Mean age: 11.26, SE
0.43) |
Netson et al. (2011) |
Longitudinal Single-arm, Open-Label |
Methylphenidate
(Individually titrated
MPH dose, 12 months)
|
Mean age: MPH group 5.21, SE 0.36 (4.26, SE
0.32) |
n=68, heterogeneous cancer types with ChT +/- RT, (Mean age:
11.11, SE 0.37) |
N.A. |
Castellino et al. (2012) |
Longitudinal Single-arm, Open-Label |
Donepezil
(10 mg/daily, 24 weeks)
|
Mean age at RT: 5.55 (4.7) |
n=11, all brain tumors with whole brain RT
(> 23.4 Gy) +/- ChT, (Mean age 11.1) |
N.A. |
Abbreviations: RT, radiotherapy; CSI, craniospinal irradiation; ChT,
chemotherapy; ±, standard deviation; SE, standard error; MPH,
methylphenidate; RCT, randomized controlled trial; N.R., Not Reported;
N.A. Not Applicable |
|
|
|
|
|